The Eve Appeal’s Post

Thanks to your support of our Rare Gynae Cancer Fund, we have awarded a grant to Dr Esther Moss at the University of Leicester and NIHR Leicester Biomedical Research Centre, to develop a blood test to diagnose uterine sarcoma. Uterine sarcomas are a rarer form of womb cancer. They make up 3 in 100 cancers in the womb (uterus). They can be difficult to diagnose as they have many of the same symptoms, and look similar on scans, to fibroids. Fibroids are non-cancerous growths in the womb. Most womb cancers are diagnosed using biopsies taken from the womb lining (called the endometrium), but these biopsies are only able to pick up 1 in 3 uterine sarcomas. This is because they begin from the muscle, rather than the lining of the womb. This can lead to a delayed or wrong diagnosis and potentially harmful treatments, which can risk spreading the cancer. Because of these issues, women and people with gynae organs with uterine sarcomas often face poor outcomes. This is an even greater problem for women from Black communities, as they have a higher risk of both fibroids and uterine sarcomas. Dr Moss and her team are aiming to develop a blood test which can distinguish between fibroids and uterine sarcomas, and could help women get the correct diagnosis and treatment sooner. Dr Moss says: “It is fantastic that The Eve Appeal and all their kind donors have supported the Rare Gynae Cancer Fund to make this project possible. Uterine sarcomas are rare cancers that can have potentially devastating impacts on patients and their families. We hope this test will make a real difference to women with uterine sarcoma.” You can read more about the research on our blog: https://bit.ly/3Dfg90L #EveResearch #ResearchNews #UterineSarcomas #WombCancer #CancerResearch #EveAppeal #TheEveAppeal